WHO Diagnostic Criteria for Prefibrotic or Early-Stage Myelofibrosis (pre-PMF)

Prefibrotic myelofibrosis (pre-PMF) is a distinct entity among chronic myeloproliferative neoplasm diagnosed according to the revised WHO classification. The clinical picture is heterogeneous, ranging from isolated thrombocytosis, mimicking essential thrombocythemia (ET), to symptoms of high-risk PMF. Continue reading

Diagnostic Criteria for Essential Thrombocytosis (ET)

Essential Thrombocytosis (ET) is the only chronic myeloproliferative disorder (MPD) without a specific phenotype. Because isolated thrombocytosis can be the initial clinical manifestation of polycythemia vera (PV), primary myelofibrosis (PMF), or chronic myelogenous leukemia, ET is not only a diagnosis of exclusion, it should also not be considered a single disease entity. Continue reading

WHO Normal Reference Ranges for Semen Quality

Semen analysis is the most important investigation of male subfertility. This is not a test for fertility but a guide for minimal standards of adequacy. What constitutes a ‘normal’ result has been a matter of debate, and recently the WHO normal ranges for semen parameters have changed.

Continue reading

WHO Analgesic Ladder for Pain Management

WHO treatment guides for cancer pain provide explanations of the pathophysiology of such pain, how to make adequate assessments, how to choose analgesics, and how to use the ladder. Early studies on its effectiveness demonstrated that the method proposed by the WHO offered inexpensive treatment and adequate relief for 70% to 90% of cancer patients with pain. Continue reading